查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848431

個人化基因組醫學市場預測至2032年：按產品、給藥方式、技術、應用、最終用戶和地區分類的全球分析

Personalized Genomic Medicine Market Forecasts to 2032 - Global Analysis By Product (Diagnostics, Therapeutics, Preventive Medicine and Other Products), Mode of Delivery, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球個人化基因組醫學市場預計到 2025 年將達到 6,639 億美元，預計到 2032 年將達到 1,1452 億美元，預測期內複合年成長率為 8.1%。

個人化基因組醫學是一種前沿的醫療保健方法，可根據每個人的基因組成量身定做治療和預防策略。透過分析個體的DNA，臨床醫生可以識別影響疾病風險、藥物反應和治療效果的基因變異。這有助於更精準的診斷、更有針對性的治療和主動的健康管理，尤其對腫瘤學、罕見遺傳疾病和藥物基因組學領域影響深遠。隨著基因定序的普及和數據整合的改進，個人化基因組醫學正在將傳統的醫療模式轉變為更精準、更具預測性、以患者為中心的系統，從而改善治療效果並減少臨床決策中的試驗。

基因組定序技術的進步

基因組定序技術的進步是個人化基因組醫療市場的關鍵驅動力。次世代定序(NGS) 的創新使基因分析更快、更準確、更具成本效益。這些改進使臨床醫生能夠識別致病突變並相應地制定治療方案。隨著定序儀越來越普及，其與常規臨床工作流程的整合也日益廣泛。準確解讀複雜基因數據的能力正在徹底改變診斷、藥物開發和預防醫學，從而推動醫療保健和研究領域的發展。

基因組檢測高成本

基因組檢測的高成本仍是個人化基因組醫療市場發展的一大限制。儘管技術不斷進步，但全面的DNA序列測定和分析仍需要昂貴的設備、熟練的人員以及複雜的數據解讀。這些經濟障礙限制了人們，尤其是在中低收入群體中，獲得個人化基因組醫療服務的機會。保險覆蓋範圍和報銷政策往往不一致，進一步限制了個人化基因組醫療的普及。在經濟高效的解決方案和更高的可負擔性得以實現之前，個人化基因組醫療的前景可能仍然遙不可及。

精準醫療的需求日益成長

精準醫療需求的不斷成長為市場帶來了巨大的機會。患者和醫療保健提供者越來越需要將遺傳、環境和生活方式等因素納入考慮的個人化治療。基因組學洞察有助於實現標靶治療，減少副作用並改善臨床療效。這種向個人化醫療的轉變對腫瘤學、罕見疾病和藥物基因組學產生了尤為顯著的影響。隨著認知度的提高和技術的進步，精準醫療正成為現代醫療保健的基石，推動基因組解決方案的投資和創新。

監管挑戰

監管挑戰威脅著個人化基因組醫學市場的成長。基因資料的複雜性、倫理考量以及全球標準差異，對臨床實施和商業化構成了障礙。基因組檢測和治療方法的核准流程冗長且不一致，可能會延遲創新解決方案的取得。資料隱私法和知情同意框架也存在很大差異，使跨境研究和病患參與變得複雜。解決這些監管問題對於確保基因組醫學的安全、公平和可擴展應用至關重要。

COVID-19的影響：

COVID-19疫情凸顯了遺傳因素在疾病感受性和治療反應中的重要性，加速了人們對個人化基因組醫學的興趣。基因組分析工具已被用於研究病毒-宿主相互作用、開發標靶治療以及了解疫苗效力。這場危機凸顯了對敏捷、數據驅動的醫療保健解決方案的需求，並推動了對基因組研究和基礎設施的投資。疫情過後，醫療保健系統擴大採用個人化方法，以提高韌性和患者預後。預計這種轉變將維持基因組醫學市場的長期成長。

預計在預測期內，生物資訊學將成為最大的細分領域。

生物資訊學領域預計將在預測期內佔據最大的市場佔有率，這得益於其在管理和解讀複雜基因組數據方面的關鍵作用。生物資訊工具能夠有效分析DNA序列、辨識疾病標記物並預測治療反應。隨著基因組資料集呈指數級成長，先進的演算法和軟體平台對於臨床決策至關重要。生物資訊學在診斷、藥物開發和個人化醫療領域的應用正在迅速擴展，使其成為基因組醫學的基本組成部分。

預計神經病學在預測期內的複合年成長率最高

預計神經病學領域將在預測期內實現最高成長率。這得歸功於神經系統疾病遺傳因素的研究日益增加。阿茲海默症、帕金森氏症和癲癇等疾病正透過基因組分析進行研究，以開發標靶治療和早期診斷工具。神經病學的個人化治療方案有望改善治療效果並減緩疾病進展。隨著認知度和資金投入的不斷增加，基因組醫學正成為神經系統治療的核心，推動該領域的快速發展和創新。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這得益於醫療保健投資的增加、基因組學研究的拓展以及精準醫療需求的不斷成長。中國、印度和日本等國家已啟動國家級舉措，以推進基因組學基礎設施建設並整合個人化醫療。該地區龐大的人口基數、日益加重的慢性病負擔以及不斷提升的數位醫療能力，共同構成了巨大的市場潛力。亞太地區在基因組學應用的採用和創新方面繼續保持領先地位。

複合年成長率最高的地區：

北美地區預計將在預測期內實現最高的複合年成長率，這得益於其強大的科研基礎設施、良好的法規結構和高昂的醫療保健支出。該地區擁有許多大型基因組學公司、學術機構和臨床試驗網路。對精準醫療的強勁需求、NGS的廣泛應用以及支持性的報銷政策進一步推動了該地區的成長。隨著個人化醫療成為主流，北美將繼續引領基因組學創新，塑造全球趨勢和標準。

免費客製化服務：

訂閱本報告的用戶可享有以下免費客製化服務之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業進行基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 二手研究資料
    • 先決條件

第3章 市場趨勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球個人化基因組醫學市場（依產品分類）

  • 診斷
  • 治療藥物
  • 預防醫學
  • 基因組資料解讀工具
  • 其他產品

6. 全球個人化基因組醫學市場（依交付類型）

  • 內部服務
  • 外包服務

7. 全球個人化基因組醫學市場（依技術分類）

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 微陣列
  • 基因編輯（CRISPR/Cas9）
  • 生物資訊學
  • 其他技術

8. 全球個人化基因組醫學市場（依應用分類）

  • 腫瘤學
  • 心血管疾病
  • 神經病學
  • 感染疾病
  • 罕見遺傳疾病
  • 藥物基因組學
  • 其他用途

9. 全球個人化基因組醫學市場（依最終用戶分類）

  • 醫院和診所
  • 診斷實驗室
  • 學術和研究機構
  • 製藥和生物技術公司
  • 其他最終用戶

第10章 全球個人化基因體醫學市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 企業概況

  • Roche
  • Illumina
  • Thermo Fisher Scientific
  • Pfizer
  • Novartis
  • Qiagen
  • Foundation Medicine
  • GE Healthcare
  • Myriad Genetics
  • AstraZeneca
  • Exact Sciences
  • 23andMe
  • Biogen
  • IBM Watson Health
  • Decode Genetics
Product Code: SMRC31626

According to Stratistics MRC, the Global Personalized Genomic Medicine Market is accounted for $663.9 billion in 2025 and is expected to reach $1,145.2 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Personalized genomic medicine is a cutting-edge approach to healthcare that tailors medical treatment and prevention strategies to an individual's genetic makeup. By analyzing a person's DNA, clinicians can identify genetic variations that influence disease risk, drug response, and treatment efficacy. This enables more accurate diagnoses, targeted therapies, and proactive health management. It is especially impactful in oncology, rare genetic disorders, and pharmacogenomics. As genomic sequencing becomes more accessible and data integration improves, personalized genomic medicine is transforming traditional care models into more precise, predictive, and patient-centered systems, enhancing outcomes and reducing trial-and-error in clinical decision-making.

Market Dynamics:

Driver:

Advancements in Genomic Sequencing Technologies

Advancements in genomic sequencing technologies are a key driver of the personalized genomic medicine market. Innovations in next-generation sequencing (NGS) have made genetic analysis faster, more accurate, and cost-effective. These improvements enable clinicians to identify disease-causing mutations and tailor treatments accordingly. As sequencing becomes more accessible, its integration into routine clinical workflows is expanding. The ability to decode complex genetic data with precision is revolutionizing diagnostics, drug development, and preventive care, fueling growth across healthcare and research sectors.

Restraint:

High Cost of Genomic Testing

High costs associated with genomic testing remain a major restraint in the personalized genomic medicine market. Despite technological progress, comprehensive DNA sequencing and analysis require expensive equipment, skilled personnel, and complex data interpretation. These financial barriers limit access, especially in low- and middle-income regions. Insurance coverage and reimbursement policies are often inconsistent, further restricting adoption. Until cost-effective solutions and broader affordability are achieved, the full potential of personalized genomic medicine may remain out of reach for many populations.

Opportunity:

Rising Demand for Precision Medicine

The rising demand for precision medicine presents a significant opportunity for the market. Patients and healthcare providers increasingly seek tailored treatments that consider genetic, environmental, and lifestyle factors. Genomic insights enable targeted therapies, reduce adverse drug reactions, and improve clinical outcomes. This shift toward individualized care is especially impactful in oncology, rare diseases, and pharmacogenomics. As awareness grows and technology advances, precision medicine is becoming a cornerstone of modern healthcare, driving investment and innovation in genomic solutions.

Threat:

Regulatory Challenges

Regulatory challenges pose a threat to the growth of the personalized genomic medicine market. The complexity of genetic data, ethical considerations, and varying global standards create hurdles in clinical implementation and commercialization. Approval processes for genomic tests and therapies can be slow and inconsistent, delaying access to innovative solutions. Data privacy laws and consent frameworks also vary widely, complicating cross-border research and patient engagement. Addressing these regulatory issues is essential to ensure safe, equitable, and scalable adoption of genomic medicine.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in personalized genomic medicine by highlighting the importance of genetic factors in disease susceptibility and treatment response. Genomic tools were used to study virus-host interactions, develop targeted therapies, and understand vaccine efficacy. The crisis underscored the need for rapid, data-driven healthcare solutions, boosting investment in genomic research and infrastructure. Post-pandemic, healthcare systems are increasingly integrating personalized approaches to improve resilience and patient outcomes. This shift is expected to sustain long-term growth in the genomic medicine market.

The bioinformatics segment is expected to be the largest during the forecast period

The bioinformatics segment is expected to account for the largest market share during the forecast period, due to its critical role in managing and interpreting complex genomic data. Bioinformatics tools enable efficient analysis of DNA sequences, identification of disease markers, and prediction of treatment responses. As genomic datasets grow exponentially, advanced algorithms and software platforms are essential for clinical decision-making. The integration of bioinformatics into diagnostics, drug development, and personalized care is expanding rapidly, making it a foundational component of genomic medicine.

The neurology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the neurology segment is predicted to witness the highest growth rate, due to increasing research into genetic factors underlying neurological disorders. Conditions such as Alzheimer's, Parkinson's, and epilepsy are being studied through genomic profiling to develop targeted therapies and early diagnostic tools. Personalized approaches in neurology offer hope for improved treatment outcomes and reduced disease progression. As awareness and funding grow, genomic medicine is becoming central to neurological care, driving rapid expansion and innovation in this segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rising healthcare investments, expanding genomics research, and growing demand for precision medicine. Countries like China, India, and Japan are advancing genomic infrastructure and launching national initiatives to integrate personalized care. The region's large population base, increasing chronic disease burden, and improving digital health capabilities contribute to strong market potential. Asia Pacific continues to lead in adoption and innovation across genomic applications.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, favorable regulatory frameworks, and high healthcare spending. The region is home to leading genomic companies, academic institutions, and clinical trial networks. Strong demand for precision therapies, widespread use of NGS, and supportive reimbursement policies further accelerate growth. As personalized medicine becomes mainstream, North America remains at the forefront of genomic innovation, shaping global trends and standards.

Key players in the market

Some of the key players in Personalized Genomic Medicine Market include Roche, Illumina, Thermo Fisher Scientific, Pfizer, Novartis, Qiagen, Foundation Medicine, GE Healthcare, Myriad Genetics, AstraZeneca, Exact Sciences, 23andMe, Biogen, IBM Watson Health, and Decode Genetics.

Key Developments:

In May 2025, Pfizer has entered into an exclusive global licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. This promising cancer therapy is undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will pay 3SBio an upfront fee of $1.25 billion, with potential milestone payments up to $4.8 billion, and tiered royalties on sales.

In February 2025, Alloy Therapeutics and Pfizer have entered into a strategic collaboration to develop a novel antibody discovery platform aimed at targeting complex disease mechanisms. Leveraging Alloy's innovative technologies, the partnership seeks to enhance the development of effective antibody-based therapies.

Products Covered:

  • Diagnostics
  • Therapeutics
  • Preventive Medicine
  • Genomic Data Interpretation Tools
  • Other Products

Mode of Deliveries Covered:

  • In-House Services
  • Outsourced Services

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Gene Editing (CRISPR/Cas9)
  • Bioinformatics
  • Other Technologies

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Rare Genetic Disorders
  • Pharmacogenomics
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Genomic Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostics
  • 5.3 Therapeutics
  • 5.4 Preventive Medicine
  • 5.5 Genomic Data Interpretation Tools
  • 5.6 Other Products

6 Global Personalized Genomic Medicine Market, By Mode of Delivery

  • 6.1 Introduction
  • 6.2 In-House Services
  • 6.3 Outsourced Services

7 Global Personalized Genomic Medicine Market, By Technology

  • 7.1 Introduction
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Microarray
  • 7.5 Gene Editing (CRISPR/Cas9)
  • 7.6 Bioinformatics
  • 7.7 Other Technologies

8 Global Personalized Genomic Medicine Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Cardiovascular Diseases
  • 8.4 Neurology
  • 8.5 Infectious Diseases
  • 8.6 Rare Genetic Disorders
  • 8.7 Pharmacogenomics
  • 8.8 Other Applications

9 Global Personalized Genomic Medicine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic and Research Institutes
  • 9.5 Pharmaceutical and Biotechnology Companies
  • 9.6 Other End Users

10 Global Personalized Genomic Medicine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Roche
  • 12.2 Illumina
  • 12.3 Thermo Fisher Scientific
  • 12.4 Pfizer
  • 12.5 Novartis
  • 12.6 Qiagen
  • 12.7 Foundation Medicine
  • 12.8 GE Healthcare
  • 12.9 Myriad Genetics
  • 12.10 AstraZeneca
  • 12.11 Exact Sciences
  • 12.12 23andMe
  • 12.13 Biogen
  • 12.14 IBM Watson Health
  • 12.15 Decode Genetics

List of Tables

  • Table 1 Global Personalized Genomic Medicine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Genomic Medicine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Genomic Medicine Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Genomic Medicine Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 5 Global Personalized Genomic Medicine Market Outlook, By Preventive Medicine (2024-2032) ($MN)
  • Table 6 Global Personalized Genomic Medicine Market Outlook, By Genomic Data Interpretation Tools (2024-2032) ($MN)
  • Table 7 Global Personalized Genomic Medicine Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 8 Global Personalized Genomic Medicine Market Outlook, By Mode of Delivery (2024-2032) ($MN)
  • Table 9 Global Personalized Genomic Medicine Market Outlook, By In-House Services (2024-2032) ($MN)
  • Table 10 Global Personalized Genomic Medicine Market Outlook, By Outsourced Services (2024-2032) ($MN)
  • Table 11 Global Personalized Genomic Medicine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 12 Global Personalized Genomic Medicine Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 13 Global Personalized Genomic Medicine Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 14 Global Personalized Genomic Medicine Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 15 Global Personalized Genomic Medicine Market Outlook, By Gene Editing (CRISPR/Cas9) (2024-2032) ($MN)
  • Table 16 Global Personalized Genomic Medicine Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 17 Global Personalized Genomic Medicine Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Personalized Genomic Medicine Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Personalized Genomic Medicine Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Personalized Genomic Medicine Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 21 Global Personalized Genomic Medicine Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 22 Global Personalized Genomic Medicine Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Personalized Genomic Medicine Market Outlook, By Rare Genetic Disorders (2024-2032) ($MN)
  • Table 24 Global Personalized Genomic Medicine Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 25 Global Personalized Genomic Medicine Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Personalized Genomic Medicine Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Personalized Genomic Medicine Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 28 Global Personalized Genomic Medicine Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 29 Global Personalized Genomic Medicine Market Outlook, By Academic and Research Institutes (2024-2032) ($MN)
  • Table 30 Global Personalized Genomic Medicine Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 31 Global Personalized Genomic Medicine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.